Pemafibrate/Tofogliflozin Hydrate(Pemafibrate/Tofogliflozin Hydrate) - 药物靶点：PPARα x SGLT2_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

PPARα x SGLT2

作用机制

PPARα激动剂(过氧化物酶体增长因子活化受体α激动剂)、SGLT2抑制剂(钠-葡萄糖协同转运蛋白-2抑制剂)

治疗领域-

在研适应症-

非在研适应症-

原研机构

Kowa Research Institute, Inc.

在研机构

Kowa Co., Ltd.Kowa Research Institute, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C22H28O7

InChIKeyZXOCGDDVNPDRIW-NHFZGCSJSA-N

CAS号1201913-82-7

查看全部结构式(2)

关联

2

项与 Pemafibrate/Tofogliflozin Hydrate 相关的临床试验

NCT05722262 / Completed临床1期

A Randomized, Open-Label, Six-Sequence, Three-Period Crossover Study to Demonstrate the Bioequivalence of Single Oral Administration of K-001 Relative to Single Oral Coadministration of Separate Tablets of K-877-ER Plus CSG452 in Healthy Adult Volunteers, and to Characterize the Food Effect on the Pharmacokinetics of K-001

The goal of this clinical trial is to demonstrate the bioequivalence of single oral administration of K-001 relative to single oral co-administration of separate tablets of K-877-ER and CSG452 in healthy adult volunteers, and to characterize the food effect on the Pharmacokinetics(PK) of K-001.

开始日期2023-02-24

申办/合作机构

Kowa Research Institute, Inc.

NCT04183478 / Unknown status临床2/3期IIT

A Randomized, Double Blinded, Parallel-controlled, Multi-center Phase II/III Study to Compare the Best Support Care (BSC) Plus K-001 Versus BSC Plus Placebo for the Third-line and Later Treatment of Patients With Advanced Pancreatic Cancer

No Standard therapy has been approved for third-line therapy of advanced pancreatic cancer. K001 is peptidoglycan prepared from the marine microorganism, with an anti-tumor activity. Previously, the phase I study of K001 has shown that K001 was safety and had some effectiveness for pancreatic patients. Now, we would like to lunch a randomized, blinded, parallel-controlled, multi-center phase II/III study to compare the best support care (BSC) plus K-001 versus BSC plus placebo for the third-line and later treatment of patients with advanced pancreatic cancer.

开始日期2017-09-26

申办/合作机构